Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call
2024年8月7日 - 8:05PM
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology
company pursuing development of targeted therapies for oncology,
today announced that it will release its financial results for the
second quarter 2024 after the market closes on Wednesday, August
14, 2024. Management will host a webcast/teleconference the same
day at 4:30 p.m. Eastern Time to discuss the results and provide a
corporate update.
Webcast and Conference Call InformationTo
participate in the teleconference, domestic callers should dial
1-800-717-1738 and international callers should dial
1-646-307-1865. A live webcast presentation can also be accessed
using this weblink:
https://viavid.webcasts.com/starthere.jsp?ei=1678191&tp_key=c55c86e8c3.
A replay of the webcast will be available on the Celcuity website
following the live event.
About Celcuity Celcuity is a
clinical-stage biotechnology company focused on development of
targeted therapies for treatment of multiple solid tumor
indications. The company's lead therapeutic candidate is
gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism
of action and pharmacokinetic properties are highly differentiated
from other currently approved and investigational therapies that
target PI3K or mTOR alone or together. A Phase 3 clinical trial,
VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant
with or without palbociclib in patients with HR+/HER2- advanced
breast cancer is currently enrolling patients. More detailed
information about the VIKTORIA-1 study can be found at
ClinicalTrials.gov. A Phase 1b/2 clinical trial, CELC-G-201,
evaluating gedatolisib in combination with darolutamide in patients
with metastatic castration resistant prostate cancer, is enrolling
patients. A Phase 3 clinical trial, VIKTORIA-2, evaluating
gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line
treatment for patients with HR+/HER2- advanced breast cancer is
expected to begin enrolling patients in the second quarter of 2025.
Celcuity is headquartered in Minneapolis. Further information about
Celcuity can be found at www.celcuity.com. Follow us on LinkedIn
and Twitter.
View source version of release on GlobeNewswire.com
Contacts:Celcuity Inc.Brian Sullivan,
bsullivan@celcuity.comVicky Hahne, vhahne@celcuity.com(763)
392-0123
ICR WestwickeMaria Yonkoski, maria.yonkoski@westwicke.com(203)
682-7167
Celcuity (NASDAQ:CELC)
過去 株価チャート
から 8 2024 まで 9 2024
Celcuity (NASDAQ:CELC)
過去 株価チャート
から 9 2023 まで 9 2024